Literature DB >> 21964212

TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms.

Jianbiao Zhou1, Qiang Yu, Wee-Joo Chng.   

Abstract

TXNIP (also named as VDUP-1 or TBP-2) was originally isolated in HL60 cells treated with Vitamin D3. Subsequently, it has been identified as a major redox regulator and a Tumor Suppressor Gene (TSG) in various solid tumors and hematological malignancies. In the present review, we will first provide an overview of TXNIP gene and protein structures, followed by a summary of the studies that have demonstrated its frequent repression in human cancers and relevant clinical significance, as well as functional characterization in animal models. We will then highlight our current knowledge of TXNIP signaling and biological functions. Next, we will discuss the evidence that clearly have demonstrated that the epigenetic silencing of TXNIP in cancer through various molecular mechanisms. The therapeutic use of small molecular inhibitors to reactivate TXNIP expression for cancer treatment will also be discussed in this review.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21964212     DOI: 10.1016/j.biocel.2011.09.005

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  47 in total

Review 1.  Molecular biology of bladder cancer.

Authors:  William Martin-Doyle; David J Kwiatkowski
Journal:  Hematol Oncol Clin North Am       Date:  2015-01-31       Impact factor: 3.722

2.  Effects of vitamin D3 stimulation of thioredoxin-interacting protein in hepatocellular carcinoma.

Authors:  James P Hamilton; James J Potter; Lahari Koganti; Stephen J Meltzer; Esteban Mezey
Journal:  Hepatol Res       Date:  2014-03-25       Impact factor: 4.288

3.  6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.

Authors:  Yanning Liu; Guohua Lou; John T Norton; Chen Wang; Irawati Kandela; Shuai Tang; Nathaniel I Shank; Pankaj Gupta; Min Huang; Michael J Avram; Richard Green; Andrew Mazar; Daniel Appella; Zhi Chen; Sui Huang
Journal:  FASEB J       Date:  2017-08-17       Impact factor: 5.191

4.  Hepatitis B virus X protein promotes hepatocellular carcinoma invasion and metastasis via upregulating thioredoxin interacting protein.

Authors:  Zhiliang He; Youjia Yu; Yunhong Nong; Lingyao Du; Cong Liu; Yong Cao; Lang Bai; Hong Tang
Journal:  Oncol Lett       Date:  2017-06-01       Impact factor: 2.967

Review 5.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

Review 6.  Coordination of nutrient availability and utilization by MAX- and MLX-centered transcription networks.

Authors:  John M O'Shea; Donald E Ayer
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

7.  UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP.

Authors:  Dian Jiao; Yi Huan; Jia Zheng; Ming Wei; Guoxu Zheng; Donghui Han; Jieheng Wu; Wenjin Xi; Feilong Wei; An-Gang Yang; Weijun Qin; He Wang; Weihong Wen
Journal:  Oncogene       Date:  2019-05-01       Impact factor: 9.867

8.  Tissue thioredoxin-interacting protein expression predicted recurrence in patients with meningiomas.

Authors:  Zheng Cai; Chenran Zhang; Yongxiang Zou; Chengyin Lu; Hongkang Hu; Jun Qian; Lei Jiang; Guohan Hu
Journal:  Int J Clin Oncol       Date:  2017-02-27       Impact factor: 3.402

9.  AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1.

Authors:  Ning Wu; Bin Zheng; Adam Shaywitz; Yossi Dagon; Christine Tower; Gary Bellinger; Che-Hung Shen; Jennifer Wen; John Asara; Timothy E McGraw; Barbara B Kahn; Lewis C Cantley
Journal:  Mol Cell       Date:  2013-02-28       Impact factor: 17.970

10.  Clinical Significance of the Thioredoxin System and Thioredoxin-Domain-Containing Protein Family in Hepatocellular Carcinoma.

Authors:  Sang Yeon Cho; Sungha Kim; Mi-Ju Son; Woo Sun Rou; Seok Hyun Kim; Hyuk Soo Eun; Byung Seok Lee
Journal:  Dig Dis Sci       Date:  2018-10-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.